Review of adherence to medications for the treatment of osteoporosis

Current Osteoporosis Reports

Volumn 4, Issue 1, 2006, Pages 21-27

  Gold, Deborah T ^a   Silverman, Stuart ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GESTAGEN; GLUCOCORTICOID; IBANDRONIC ACID; MONOCLONAL ANTIBODY; RALOXIFENE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLENDRONATE; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; DOCTOR PATIENT RELATION; DRUG WITHDRAWAL; FRACTURE; HEALTH BELIEF; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PRACTITIONER; HORMONAL THERAPY; HUMAN; LUMBAR SPINE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; REVIEW; RISK FACTOR; SELF REPORT; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 33646081066     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-006-0011-8     Document Type: Review

References (29)

1. Sclar DA, Chin A, Skaer TL, et al.: Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991, 13:489-495. Health education may improve adherence.
2. Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460. Adherence is improved with weekly versus daily bisphosphonates.
3. Sikka R, Xia F, Aubert RE: Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
4. Dezii CM: Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001, 10:42-45.
5. Hart JT: Commentary: can health outputs of routine practice approach those of clinical trials? Int J Epidemiol 2001, 30:1263-1267.
6. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353:487-497. An excellent review of the problem of poor adherence with all therapies.
7. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310. Another excellent review of the relationship between dosing and compliance.
8. Berg JS, Dischler J, Wagner DJ, et al.: Medication compliance: a healthcare problem. Ann Pharmacother 1993, 27(Suppl 9):S1-S24.
9. Miller NH: Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997, 102:43-49.
10. Tosteson AN, Grove MR, Hammond CS, et al.: Early discontinuation of treatment for osteoporosis. Am J Med 2003, 115:209-216. An early article on poor adherence using telephone survey.
11. Hamilton B, McCoy K, Taggart H: Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003, 14:259-262.
12. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J: Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48:271-287. A large review of insurance claims data showing poor adherence with bisphosphonate therapy.
13. Ettinger M, Gallagher R, Amonkar M, et al.: Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate [abstract]. Arthritis Rheum 2004, 50(Suppl 1):S513-S514.
14. Boccuzzi SF, Omar SH, Kahler MA: Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Paper Presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Rome, Italy; March 2005.
15. Turbi C, Herrero-Beaumont G, Acebes JC, et al.: Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004, 26:245-256.
16. Curtis JR, Westfall AO, Allison JJ, et al.: Persistence and adherence to alendronate and risedronate among chronic glucocorticoid users [abstract]. Arthritis Rheum 2005, 52(Suppl 9):s374. This abstract is the first to show that patients at high risk for fracture on glucocorticoids have similar problems with adherence.
17. Papaioannou A, Ioannidis G, Adachi JD, et al.: Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003, 14:808-813. This paper showed decreased BMD response and a trend toward greater 10 year fracture risk in nonadherent patients using a national database of tertiary specialists.
18. Solomon DH, Avorn J, Katz JN, et al.: Compliance with osteoporosis medications. Arch Intern Med 2005, 165:2414-2419.
19. O'Brien MK, Petrie K, Raeburn J: Adherence to medication regimens: updating a complex medical issue. Med Care Rev 1992, 49:435-454.
20. Bender B, Milgrom H, Rand C: Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol 1997, 79:177-186.
21. Col N, Fanale JE, Kronholm P: The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990, 150:841-845. Poor adherence results in increased hospitalizations
22. Yood RA, Emani S, Reed JI, et al.: Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003, 14:965-968. This paper showed the adverse consequences of poor adherence on BMD.
23. Clowes JA, Peel NF, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:1117-1123. Monitoring with biochemical markers did not improve compliance but increased health care provider interaction did.
24. Caro JJ, Ishak KJ, Huybrechts KE et al.: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008. This paper was one of the first to show the adverse consequences of poor adherence on fracture rate.
25. Siris E, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non-vertebral fractures from a US claims database. JAMA 2006, In press This paper shows us the adverse consequences of poor adherence in terms of increased nonvertebral fracture rates.
26. Pickney CS, Arnason JA: Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 2005, 16:1156-1160.
27. Roth MT, Ivey JL: Self reported medication use in community residing older adults: a pilot study. Am J Geriat Pharmacother 2005, 3:196-204. This paper discusses the polypharmacy seen in elderly adults
28. Nattras S, Silverman S, Drinkwater B: Effectiveness of education and/or NTx results as a means of encouraging compliance to alendronate. Presented at the World Congress on Osteoporosis. Chicago, IL; May 2000.
29. Delmas PD, Vrijens B, Roux C, et al.: Reinforcement Message Based on Bone Turnover Marker Response Influences Long-Term Persistence with Risedronate in Osteoporosis: The IMPACT Study Abstract M330. Presented at the meeting of the American Society of Bone and Mineral Research. Minneapolis, MN, September 2003.